Regeneron's New Anticoagulant Surpasses Enoxaparin and Matches Eliquis in Phase 2 Trials
Regeneron's phase 2 trials revealed significant progress in the development of its anticoagulant treatments, with REGN7508 and REGN9933 showing impressive outcomes against existing anticoagulants during knee replacement surgery[1][2]. REGN7508, which targets the catalytic domain of factor XI, surpassed enoxaparin by reducing venous thromboembolism (VTE) incidents to 7% compared to enoxaparin's 21% and proved non-inferior to Eliquis with a VTE rate at 12%[1][2]. REGN9933, on the other hand, demonstrated a 17% VTE incidence rate, indicating non-inferiority to enoxaparin but not matching Eliquis' efficacy completely[2]. Both treatments maintained a favorable safety profile with minimal bleeding, marking a step forward in developing safer anticoagulation therapies[1][2].
References
Explore Further
What are the specific safety profile details of REGN7508 and REGN9933 in terms of bleeding risks compared to factor Xa-targeting anticoagulants?
How do REGN7508 and REGN9933's mechanisms of action contribute to their performance in anticoagulant therapies?
What are the potential challenges Regeneron might face in their upcoming phase 3 trials?
How does Regeneron's strategy of targeting different domains of factor XI set its therapies apart from those of competitors like Bayer and BMS/Johnson & Johnson?
What are the implications of Regeneron's phase 2 trial outcomes for future anticoagulant market dynamics and patient treatment options?